United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alimera sciences ltd - fluocinolone acetonide - prolonged-release intravitreal implant - 190microgram

Ireland - English - HPRA (Health Products Regulatory Authority)

alimera sciences europe limited, - fluocinolone acetonide - intravitreal implant in applicator - 190 microgram(s) - fluocinolone acetonide

Australia - English - Department of Health (Therapeutic Goods Administration)

specialised therapeutics alim pty ltd - fluocinolone acetonide, quantity: 190 microgram - implant - excipient ingredients: polyvinyl alcohol; pmda/oda copolymer; dimeticonol; ethyltriacetoxysilane; methyltriacetoxysilane; dibutyltin diacetate; silica dimethicone silylate - iluvien is indicated for the treatment of diabetic macular oedema (dme) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (iop).

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dexamethasone, quantity: 700 microgram - implant - excipient ingredients: polyglactin - ozurdex is indicated for the treatment of:,- diabetic macular oedema (dme),- macular oedema due to branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo).,- non-infectious uveitis affecting the posterior segment of the eye. ozurdex is indicated for the treatment of diabetic macular oedema (dme).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept, quantity: 40 mg/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; sucrose; water for injections; polysorbate 20 - eylea (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet amd) - visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo) - diabetic macular oedema (dme) - visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo) - visual impairment due to myopic choroidal neovascularisation (myopic cnv)

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept, quantity: 40 mg/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sucrose; polysorbate 20; sodium chloride; water for injections; dibasic sodium phosphate heptahydrate - eylea (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet amd); - visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo); - diabetic macular oedema (dme); - visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo); - visual impairment due to myopic choroidal neovascularisation (myopic cnv)

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

allergan ltd - dexamethasone - implant - 700microgram

Israel - English - Ministry of Health

bayer israel ltd - aflibercept - solution for intravitreal injection - aflibercept 40 mg/ml - aflibercept - eylea is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (amd)• visual impairment due to macular oedema secondary to retinal vein occlusion (branch crvo or central rvo)• visual impairment due to diabetic macular oedema (dme)• visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

allergan pharmaceuticals ltd, ireland - dexamethasone - intravitreal implant in applicator - 700 µg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

abbvie deutschland gmbh, germany - dexamethasone - intravitreal implant in applicator - 700 µg